Dark

MCRB
Seres Therapeutics, Inc.
stock NASDAQ

Market Open

Oct 2, 2026 2:09:13 PM EDT

2.93USD0.000%(0.00)81,274

2.91Bid 3.00Ask 0.09Spread

Pre-market

Oct 2, 2026 9:12:30 AM EDT

3.04USD+3.754%(+0.11)5,182

After-hours

Oct 1, 2026 4:12:30 PM EDT

2.93USD+0.515%(+0.02)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

07:00AM EST Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022 Business Wire

Jan 19, 2022

05:01PM EST Seres Therapeutics Says New England Journal Of Medicine Publishes Data From ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 In Recurrent C. Difficile Infection Benzinga

05:01PM EST New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection Business Wire

Jan 4, 2022

07:00AM EST Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 16, 2021

07:16AM EST Seres Reports Preliminary Microbiome Data Analyses From Phase 2b ECO-RESET Study Of SER-287 In Ulcerative Colitis RTTNews

07:02AM EST Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis; Co. Reports 'microbiome data demonstrate the successful engraftment of SER-287' Benzinga

07:00AM EST Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis Business Wire

Nov 30, 2021

04:43PM EST Seres Therapeutics Announces First Patient Enrolled In Phase 1b Study Of SER-155 Investigational Microbiome Therapeutic To Reduce The Risk Of Antibiotic-Resistant Bacterial Infections And Graft-Versus-Host Disease Benzinga

07:05AM EST Seres Therapeutics Enrolls First Patient In SER-155 Phase 1b Study RTTNews

07:00AM EST Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD) Business Wire

Nov 24, 2021

07:00AM EST Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference Business Wire

Nov 11, 2021

11:55AM EST Looking Into Seres Therapeutics's Return On Capital Employed Benzinga

Nov 10, 2021

02:30PM EST Mid-Afternoon Market Update: Nasdaq Tumbles 300 Points; PubMatic Shares Gain After Q3 Results Benzinga

10:11AM EST Mid-Morning Market Update: Markets Edge Lower; US Inflation Rate Increases To 6.2% Benzinga

07:18AM EST Seres Therapeutics Q3 EPS $0.72 Up From $(0.36) YoY, Sales $126.72M Up From $1.42M YoY Benzinga

07:00AM EST Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Business Wire

05:57AM EST Bacthera and Seres Therapeutics Announced Collaboration for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

02:17AM EST Bacthera, Seres Collaborate For Commercial Manufacturing Of SER-109, Treatment Against Recurrent C. Difficile Infection RTTNews

02:00AM EST Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection Business Wire

Nov 4, 2021

07:00AM EDT Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021 Business Wire

Oct 26, 2021

07:59AM EDT UPDATE: Seres Says 'Study shows that SER-109 reduced the risk of recurrent C. difficile infection in patients with risk factors for recurrence, including acid-reducing medications' Benzinga

07:59AM EDT Seres Therapeutics Highlights Presentation Of Late-Breaking Phase 3 Data On Its SER-109 In Recurrent C. Difficile Infection At American College Of Gastroenterology Meeting Oct. 26 At 6:25 p.m. EDT Benzinga

07:14AM EDT Seres Presents Phase 3 Data On Investigational Microbiome Therapeutic SER-109 In Recurrent C. Difficile Infection RTTNews

07:00AM EDT Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting Business Wire

Oct 13, 2021

10:12AM EDT Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize PR Newswire

Oct 2, 2021

10:31PM EDT Seres : Phase 3 Study Shows SER-109 Associated With RTTNews

01:15PM EDT Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021 Business Wire

Sep 29, 2021

02:01PM EDT Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection Benzinga

Sep 15, 2021

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

07:18AM EDT Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. Difficile Infection Benzinga

07:07AM EDT Seres Therapeutics Enrolls 300 Subjects With Phase 3 ECOSPOR IV Open-Label Extension Study Of SER-109 RTTNews

07:00AM EDT Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection Business Wire

Sep 14, 2021

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 7, 2021

07:00AM EDT Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences Business Wire

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 5, 2021

07:00AM EDT Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference Business Wire

Aug 3, 2021

07:55AM EDT The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business Benzinga

07:34AM EDT Recap: Seres Therapeutics Q2 Earnings Benzinga

07:28AM EDT Seres Therapeutics Q2 Net Loss $48.3 Mln Vs. Net Loss Of $20.7 Mln Prior Year RTTNews

07:13AM EDT Seres Therapeutics Q2 Sales $5.26M Miss $5.34M Estimate Benzinga

07:10AM EDT Seres Therapeutics Q2 EPS $(0.53) Misses $(0.37) Estimate Benzinga

07:00AM EDT Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Business Wire

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

07:00AM EDT Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021 Business Wire

Jul 23, 2021

03:02PM EDT Analyst Ratings For Seres Therapeutics Benzinga

12:02PM EDT UPDATE: Chardan On Seres Therapeutics Price Target Decrease: Firm Notes No Clinical Differences/Statistical Significance Observed Among Three Treatment Arms Of SER-287 Cohorts; Warns On Mgmt Inability To 'Ascribe Lack Of Efficacy To Any Specific Factors' Benzinga

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021 Benzinga

10:18AM EDT Canaccord Genuity Maintains Buy on Seres Therapeutics, Lowers Price Target to $29 Benzinga

08:52AM EDT Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $16 Benzinga

08:00AM EDT Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $18 Benzinga

07:59AM EDT 10 Biggest Price Target Changes For Friday Benzinga

06:41AM EDT HC Wainwright & Co. Maintains Buy on Seres Therapeutics, Lowers Price Target to $25 Benzinga

05:12AM EDT Goldman Sachs Downgrades Seres Therapeutics to Sell, Lowers Price Target to $7 Benzinga

Jul 22, 2021

03:20PM EDT Series Therapeutics Shares Quiet, JMP Securities Issues Mid-Day Note; Says 'Strongly View Results Of Ph2 ECO-RESET Trial For Mild-To-Moderate UC Evaluating SER-287 (two-arms) vs. PBO Is An Isolated Story (that is still evolving)' Benzinga

02:42PM EDT Mid-Afternoon Market Update: Dow Rises Over 50 Points; ImmunoPrecise Antibodies Shares Spike Higher Benzinga

12:51PM EDT Mid-Day Market Update: Crude Oil Up 1.5%; Seres Therapeutics Shares Plunge Benzinga

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

10:08AM EDT Mid-Morning Market Update: Markets Mostly Lower; AT&T Beats Q2 Estimates Benzinga

08:18AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO Benzinga

08:17AM EDT Shares of Seres Therapeutics, Inc. (MCRB) are down more than 55% in pre-market on Thursday after the company said Phase 2 study of its ulcerative colitis drug candidate failed to meet the primary endpoint. RTTNews

07:33AM EDT Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis Business Wire

07:23AM EDT Seres Therapeutics Inc. (MCRB) said that a phase 2b ECO-RESET study, which evaluated SER-287 in patients with mild-to-moderate ulcerative colitis, did not meet its primary endpoint of improving clinical remission rates compared to placebo. Both dosing regimens of SER-287 were generally well tolerated. RTTNews

07:17AM EDT Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis; Co. reports 'Primary endpoint of clinical remission compared to placebo was not achieved' Benzinga

07:10AM EDT Seres : Phase 2b ECO-RESET Study Of SER-287 On Mild-to-moderate Ulcerative Colitis Fails To Meet Primary Endpoint RTTNews

07:00AM EDT Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis Business Wire

Jul 2, 2021

05:08AM EDT Nestl Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases Benzinga

Jul 1, 2021

07:10AM EDT Seres Therapeutics, Nestl Health Science Announce SER-109 Co-Commercialization License Agreement; Seres To Receive $175M Upfront Payment And Additional $125M Upon FDA Approval Of SER-109 Benzinga

07:10AM EDT Seres Therapeutics, Nestl Health Science Unveil SER-109 Co-Commercialization License Deal RTTNews

07:00AM EDT Seres Therapeutics, Nestl Health Science Announce SER-109 Co-Commercialization License Agreement Business Wire

Jun 28, 2021

11:07AM EDT Seres Therapeutics Option Alert: Aug 20 $25 Calls at the Ask: 901 @ $5.3 vs 5391 OI; Earnings 7/27 Before Open [est] Ref=$24.1811 Benzinga

Jun 14, 2021

07:52PM EDT at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative PR Newswire

Jun 10, 2021

07:00AM EDT Seres Therapeutics to Host Virtual Investor Event on June 21, 2021 Business Wire

07:00AM EDT Seres Therapeutics to Present at JMP Securities Life Sciences Conference Business Wire

Jun 4, 2021

02:32PM EDT Seres Therapeutics Presents Research From Early-Stage Microbiome Therapeutic Oncology Programs At ASCO 2021 Meeting Benzinga

02:30PM EDT Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire

Jun 1, 2021

11:48AM EDT Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials Benzinga

09:31AM EDT Seres Therapeutics Inc. (MCRB) said the U.S. Food and Drug Administration has indicated that studies for SER-155 may proceed under an Investigational New Drug or IND application. RTTNews

08:12AM EDT Seres Therapeutics Announces FDA Clearance Of IND For SER-155 RTTNews

08:00AM EDT Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD) Business Wire

May 25, 2021

08:00AM EDT Seres Therapeutics to Present at Upcoming Virtual Investor Conferences Business Wire

06:01AM EDT Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological PR Newswire

May 21, 2021

12:15PM EDT Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021 Business Wire

May 20, 2021

08:10AM EDT Seres Therapeutics Announces David Arkowitz Executive Vice President, Chief Financial Officer and Head of Business Development Benzinga

08:00AM EDT Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development Business Wire

May 19, 2021

05:25PM EDT Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021 Benzinga

05:22PM EDT Seres Therapeutics to Present Clinical Research on the Microbiome's Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire

09:46AM EDT Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening RTTNews

09:04AM EDT Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat PR Newswire

May 12, 2021

07:00AM EDT Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference Business Wire

May 11, 2021

08:00AM EDT Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting Business Wire

May 5, 2021

06:25AM EDT HC Wainwright & Co. Maintains Buy on Seres Therapeutics, Raises Price Target to $46 Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

07:27AM EDT Seres Therapeutics: Q1 Earnings Insights Benzinga

07:26AM EDT Seres Therapeutics Q1 Loss Per Share $0.39 Vs Loss $0.28 Last Year RTTNews

07:20AM EDT Seres Therapeutics Q1 EPS $(0.39) Misses $(0.31) Estimate, Sales $5.72M Miss $6.45M Estimate Benzinga

07:00AM EDT Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates Business Wire

Apr 28, 2021

07:00AM EDT Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021 Business Wire

Apr 15, 2021

07:00AM EDT Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit Business Wire

Mar 30, 2021

09:30AM EDT Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion PR Newswire

Mar 12, 2021

07:08AM EST Seres Therapeutics To Present At 31st Annual Oppenheimer Healthcare Conference Mar. 16 Benzinga

07:00AM EST Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference Business Wire

Mar 8, 2021

08:36AM EST Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development Benzinga

07:16AM EST Seres Therapeutics Reports Discontinuation Of Enrollment In SER-401 Study In Metastatic Melanoma RTTNews

07:06AM EST Seres Therapeutics Discontinues Enrollment In SER-401 Study In Metastatic Melanoma, Citing 'challenges in enrollment due to the COVID-19 pandemic, subsequent anticipated time to study completion, and progress in its preclinical oncology pipeline' Benzinga

07:00AM EST Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma Business Wire

Mar 5, 2021

10:46AM EST Seres Therapeutics shares were trading higher after Chardan Capital upgraded the stock from Neutral to Buy and raised its price target from $27.50 to $30 per share. Benzinga

10:29AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 5, 2021 Benzinga

08:20AM EST Chardan Capital Upgrades Seres Therapeutics to Buy, Raises Price Target to $30 Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

07:19AM EST Seres Therapeutics Q4 Net Loss $18.3 Mln Vs. Net Loss $18.8 Mln Last Year RTTNews

07:15AM EST Seres Therapeutics Reports FY20 EPS $(1.12) Up From $(1.24) YoY, Sales $33.215M Down From $34.505M YoY Benzinga

07:13AM EST Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis Benzinga

07:00AM EST Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates Business Wire

07:00AM EST Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis Business Wire

03:40AM EST Earnings Scheduled For March 2, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

08:00AM EST Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences Business Wire

Feb 25, 2021

07:01AM EST Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire

Feb 24, 2021

07:00AM EST Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021 Business Wire

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 19, 2021

07:09AM EST Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium On Jan. 20 Benzinga

07:01AM EST Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium Business Wire

Jan 6, 2021

07:18AM EST Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results In Journal Gastroenterology RTTNews

07:00AM EST Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference Business Wire

07:00AM EST Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology Business Wire

Dec 23, 2020

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 23, 2020 Benzinga

06:38AM EST JMP Securities Initiates Coverage On Seres Therapeutics with Market Perform Rating Benzinga

Dec 16, 2020

10:00AM EST 10 Healthcare Stocks That Thrived In 2020 Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

07:00AM EST Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences Business Wire

Nov 18, 2020

07:30AM EST The Daily Biotech Pulse: Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted Benzinga

Nov 9, 2020

07:18AM EST Seres Therapeutics Q3 EPS $(0.36) Misses $(0.25) Estimate, Sales $1.42M Down From $7.03M YoY Benzinga

07:16AM EST Seres Therapeutics Q3 Loss Per Share $0.36 Vs Loss $0.23 Last Year RTTNews

07:00AM EST Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates Business Wire

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

07:05AM EST Seres Therapeutics Reports Initiation Of Phase 1b Trial Of SER-301 For Treatment Of Ulcerative Colitis Benzinga

07:00AM EST Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis Business Wire

Nov 2, 2020

07:00AM EST Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020 Business Wire

Oct 22, 2020

07:26AM EDT Seres Therapeutics Names David Ege EVP, CTO And Jayne Gansler As EVP And CPO RTTNews

07:00AM EDT Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer Business Wire

Oct 12, 2020

07:10AM EDT Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting Benzinga

Sep 22, 2020

07:00AM EDT Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit Business Wire

Sep 21, 2020

10:11AM EDT Canaccord Genuity Maintains Buy on Seres Therapeutics, Raises Price Target to $42 Benzinga

Sep 18, 2020

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga

07:41AM EDT Chardan Capital Downgrades Seres Therapeutics to Neutral, Announces $27.5 Price Target Benzinga

Sep 14, 2020

07:00AM EDT Seres Therapeutics to Present at Upcoming Investor Conferences Business Wire

Sep 11, 2020

07:09AM EDT Seres Therapeutics Obtains Correspondence From FDA Following Positive SER-109 Phase 3 Study Results RTTNews

07:01AM EDT Seres Therapeutics Reports FDA Correspondence Following SER-109 Phase 3 Results: FDA Reaffirmed Prior Guidance Regarding Efficacy Requirements Benzinga

07:00AM EDT Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results Business Wire

Aug 18, 2020

09:48AM EDT Benzinga's Top Upgrades, Downgrades For August 18, 2020 Benzinga

06:10AM EDT A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Walmart Earnings Benzinga

06:08AM EDT A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Walmart, Home Depot Earnings Benzinga

05:22AM EDT Piper Sandler Initiates Coverage On Seres Therapeutics with Overweight Rating, Announces Price Target of $40 Benzinga

Aug 17, 2020

09:05AM EDT What To When You Start The Day In The Red Benzinga

Aug 12, 2020

10:08PM EDT Seres Therapeutics Prices Underwritten Public Offering Of 10.50 Mln Shares At $21.50/shr RTTNews

09:39PM EDT Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock Business Wire

09:41AM EDT Benzinga's Top Upgrades, Downgrades For August 12, 2020 Benzinga

Aug 11, 2020

05:48PM EDT Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Business Wire

11:28AM EDT HC Wainwright & Co. Maintains Buy on Seres Therapeutics, Raises Price Target to $41 Benzinga

10:03AM EDT Benzinga's Top Upgrades, Downgrades For August 11, 2020 Benzinga

08:44AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:07AM EDT Jefferies Upgrades Seres Therapeutics to Buy, Raises Price Target to $29 Benzinga

04:58AM EDT Chardan Capital Maintains Buy on Seres Therapeutics, Raises Price Target to $32.5 Benzinga

Aug 10, 2020

02:32PM EDT Mid-Afternoon Market Update: Dow Surges 300 Points; Omeros Shares Spike Higher Benzinga

01:39PM EDT Seres Therapeutics Shares Quiet As Traders Circulate Word Of New Street-High Price Target Of $30 Set By Oppneheimer Benzinga

12:20PM EDT Mid-Day Market Update: Crude Oil Rises 2%; Eastman Kodak Shares Plummet Benzinga

11:34AM EDT Return On Capital Employed Overview: Seres Therapeutics Benzinga

10:27AM EDT Mid-Morning Market Update: Markets Mostly Higher; Marriott Misses Q2 Expectations Benzinga

10:14AM EDT Morning Market Stats in 5 Minutes Benzinga

09:53AM EDT Shares of Seres Therapeutics, Inc. (MCRB) increased more-than four-fold after the therapeutics company reported positive results from a late stage trial of its SER-109 for recurrent C. difficile infections, or inflammation of the colon caused by Clostridium difficile bacteria. RTTNews

06:35AM EDT Seres Therapeutics Announces Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection Met The Primary Endpoint Benzinga

Jul 29, 2020

02:13PM EDT Seres Therapeutics Option Alert: Sep 18 $2.5 Puts Sweep (7) near the Bid: 341 @ $0.701 vs 331 OI; Ref=$4.06 Benzinga

Jul 28, 2020

09:41AM EDT Recap: Seres Therapeutics Q2 Earnings Benzinga

07:09AM EDT Seres Therapeutics Q2 EPS $(0.28) Down From $(0.24) YoY, Sales $6.04M Down From $12.53M YoY Benzinga